Treatment with high-dose intravenous immunoglobulin (IVIG) appears to be an effective way of reducing steroid requirements in patients with steroid-dependent asthma, according to a recent report.
Dr. Lynda C. Schneider and colleagues, from Harvard Medical School in Boston, assessed the respiratory outcomes of five patients, 4 to 32 years of age, with steroid-dependent asthma who received six monthly infusions of IVIG at a dose of 2 g/kg. The researchers’ findings are published in the September issue of Pediatric Asthma, Allergy, and Immunology.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!